NCT06223607
Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
Recruiting
Not specifiedAges 18+ObservationalMethodist Health SystemInvestigator-initiated
~300 participants
Updated 2026-06-10 on ClinicalTrials.gov
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of bleeding
Measured over 1 year
Conditions
Where it's being run
1 sites across 1 statesTexas1
Study leadership
- Jessica Rago Crotty, Pharm D · PRINCIPAL_INVESTIGATOR · Methodist Midlothian Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
≥ 18 years
PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
Thrombocytopenia defined as platelet count \<100 x103 /µL on at least one occasion prior to PCI
At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor
Exclusion
Death within 48 hours post-PCI
DAPT prior to cardiac catheterization
What this trial measures
- Incidence of bleeding1 year
To evaluate the difference in bleeding rates in patients with chronic thrombocytopenia maintained on DAPT with clopidogrel compared to patients maintained on DAPT with ticagrelor.